Debt-free Balance SheetA zero-debt, equity-stable balance sheet materially lowers financial risk and preserves strategic optionality. Over months this supports consistent R&D and product engineering investment, resilience through contract seasonality, and the ability to fund opportunistic M&A or partnerships without refinancing strain.

High Gross And Operating MarginsSustained high gross and operating margins reflect a software-driven, scalable model typical in image-based medical solutions. Durable margin structure enables reinvestment in product development and supports above-average returns on incremental revenue, cushioning profitability during moderate top-line softness.

Strong Free Cash Flow Linkage To EarningsFree cash flow that generally tracks reported earnings indicates real cash-generating operations and funding capacity for dividends, capex, and selective M&A. Over the medium term this underpins capital allocation flexibility and reduces reliance on external financing for growth or shareholder returns.

Bears Say

Three-year Revenue DeclineA persistent multi-year top-line contraction signals structural challenges in demand, customer retention, or competitive positioning. Continued revenue declines can erode operating leverage, limit reinvestment capacity for product roadmap execution, and ultimately pressure long-term revenue growth prospects and market share.

Volatile Cash Flow Conversion And FCF GrowthWide swings in cash conversion and episodic FCF declines reduce predictability of internal funding and complicate sustainable capital allocation. Over several months this volatility can force conservative dividend or investment decisions, raising execution risk for long-term product development and commercialization plans.

Step-down In Profitability And Returns Since 2022A material drop in net margin and moderated returns since 2022 points to weakening pricing power, mix shifts, or higher operating costs. Persistently lower profitability reduces reinvestment capacity, compresses returns on equity, and makes funding growth initiatives or maintaining dividend policies more challenging over the medium term.

0HI7 FAQ

What was MeVis Medical Solutions AG’s price range in the past 12 months?

MeVis Medical Solutions AG lowest share price was €23.40 and its highest was €26.80 in the past 12 months.

What is MeVis Medical Solutions AG’s market cap?

MeVis Medical Solutions AG’s market cap is €45.50M.

When is MeVis Medical Solutions AG’s upcoming earnings report date?

MeVis Medical Solutions AG’s upcoming earnings report date is Jun 01, 2026 which is in 95 days.

How were MeVis Medical Solutions AG’s earnings last quarter?

MeVis Medical Solutions AG released its earnings results on Jan 29, 2026. The company reported €0.419 earnings per share for the quarter, beating the consensus estimate of N/A by €0.419.

Is MeVis Medical Solutions AG overvalued?

According to Wall Street analysts MeVis Medical Solutions AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does MeVis Medical Solutions AG pay dividends?

MeVis Medical Solutions AG does not currently pay dividends.

What is MeVis Medical Solutions AG’s EPS estimate?

MeVis Medical Solutions AG’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does MeVis Medical Solutions AG have?

MeVis Medical Solutions AG has 1,820,000 shares outstanding.

What happened to MeVis Medical Solutions AG’s price movement after its last earnings report?

MeVis Medical Solutions AG reported an EPS of €0.419 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of MeVis Medical Solutions AG?

Currently, no hedge funds are holding shares in GB:0HI7

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

MeVis Medical Solutions Stock Smart Score

Neutral

Fundamentals

Return on Equity

24.14%

Trailing 12-Months

Asset Growth

-6.09%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

MeVis Medical Solutions AG

MeVis Medical Solutions AG develops, markets, and sells software for analyzing and evaluating image data to equipment manufacturers of medical devices, providers of medical IT platforms, and clinical end customers in the United States and Europe. The company's clinical focuses are image-based early detection and diagnosis of epidemiologically important diseases, such as breast, lung, liver, and neurological disorders. It offers X-ray modalities, including computed tomography, digital mammography, digital tomosynthesis, magnetic resonance imaging, and digital sonography; and provides services in the field of software programming for medical technology companies, which comprise provision of software developers, product and project managers, application specialists, and test engineers. The company also offers three-dimensional technical visualizations; and interactive online training to enhance the diagnostic skills of clinicians, as well as internet-based special applications in teleradiology. In addition, its services are used for technical visualization and online training. The company was founded in 1992 and is based in Bremen, Germany. MeVis Medical Solutions AG is a subsidiary of Varex Imaging Deutschland AG.